HPV POSITIVE OROPHARYNGEAL CARCINOMA the radiation oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
|
|
|
- Peter Norman
- 5 years ago
- Views:
Transcription
1 HPV POSITIVE OROPHARYNGEAL CARCINOMA the radiation oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
2 HEAD AND NECK CANCER -HPV Change in incidence:
3 HEAD AND NECK CANCER -HPV Change in incidence: Chaturvedi AK J Clin Oncol 2011
4 TWO DISTINCT HEAD AND NECK CANCERS GillisonM J NatlCancer Inst2008
5 OVERALL SURVIVAL BY HPV STATUS IN PROSPECTIVE PHASE III RT TRIALS Regimen HR (95% CI) Author Induction + CRT (ECOG) 0,36 (0,15-0,85) Fakhry CRT (TROG 2.2) 0,29 (NR) Rischin CRT (RTOG 0129) 0,44 (0,2-0,69) Ang Induction + CRT (TAX324) 0,20 (NR) Settle Radiation(DAHANCA5) 0,44 (0,28-0,68) Lassen
6 INFLUENCE OF HPV AFTER CONVENTIONAL RADIOTHERAPY IN HNSCC (5FX/WEEK) DAHANCA 5 (N=156) HPV/p16-positivity is a favourable and strong independent prognostic factor in head and neck cancer radiotherapy Lassen P J ClinOncol2009
7 CHEMORADIOTHERAPY: RTOG % 3y DFS <50% 3y DFS AngKK New Eng J Med 2010
8 POSTOPERATIVE RADIOCHEMOTHERAPY Lohaus F Radiother Oncol 2014
9 Influence of HPV for all HNC? OS by p16 status stage III-IV OPC(E) versus st III-IV non-opc(f) after (chemo)rt Lassen P et al RadiotherOncol 2014
10 NEED FOR NEW CLASSIFICATION HPV+ HPV- HuangC et al JCO 2015
11 HuangC et al JCO 2015
12 Clinical and Pathological T categories T1 T2 T3 T4 Tumour 2 cm or less in greatest dimension Tumourmore than 2 cm but not more than 4 cm Tumour more than 4 cm in or extension to lingual surface of epiglottis Tumourinvades any of the following: larynx, deep/ extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), medial pterygoid, hard palate, mandible*, lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base; or encases carotid artery Clinical N categories N0 No regional lymph node metastasis Clinical N1 Unilateral metastasis, in lymph node(s), all 6 cm or less Stage I T1,T2 N0,1 M0 N2 Contralateral or bilateral metastasis in lymph node(s), all 6 cm or less in greatest dimension Stage II T1,T2 N2 T3 N0,N1,N2M0 M0 N3 Metastasis in lymph node(s) greater than 6 cm in dimension Stage III T1-T4 N3 M0 T4 Any N M0 Stage IV Any T Any N M1
13 WHY BETTER PROGNOSIS? Higher locoregional control: HPV-positive tumors may harbor fewer or different genetic alterations, which can be associated with better response to therapy Cancer Genome Atlas Network Nature 2015
14 WHY BETTER PROGNOSIS? Higher locoregional control: HPV-positive tumors may harbor fewer or different genetic alterations, which can be associated with better response to therapy HPV-positive tumours have higher radiosensitivity, due to compromised DNA repair capacity In vitro data suggest high number of residual DNA double strand breaks after irradiation Compromised DNA repair capacity (RieckmannRadiotherOncol2013, Gupta IJROBP 2009, Kimple Cancer Res 2013, Busch Radiother Oncol 2013, Dok Cancer Res 2014 )
15 UNDERLYING BIOLOGY P16- P16- P16 + P16 + Dok R Cancer Res2014
16 WHY BETTER PROGNOSIS? Higher locoregional control: HPV-positive tumors may harbor fewer or different genetic alterations, which can be associated with better response to therapy HPV-positive tumours have higher radiosensitivity, probably due to intact apoptotic response to radiation Immunologic response may play a role in the improved response to radio- and chemotherapy in HPV-positive tumours d rates secondary tumors Less field cancerization d frequency of poor prognostic factors Performance status, T-stage, younger age, reduced smoking
17 HEAD AND NECK CANCER AND HPV
18 HEAD AND NECK CANCER -HPV Risicofactoren Adjusted odds ratios for HPV negative cancer Adjusted odds ratios for HPV positive cancer
19 RISK FACTORS FOR HEAD AND NECK CANCERS HPV- Smoking Drinking HPV+ High number of oral sex partners High number of open mouth kissing partners Young age of first sexual experience
20 HPV AND OROPHARYNGEAL CANCER
21 HPV POSITIVE DISEASE Clinical observations: HPV positive tumors tend to respond better to radiotherapy RT alone Radiochemotherapy Postoperative radio(chemo)therapy Reasons? In vitro/ in vivo: Compromised DNA repair capacity (Rieckmann Radiother Oncol 2013, Gupta IJROBP 2009, Kimple Cancer Res 2013)
22 UNDERLYING BIOLOGY P16- P16- P16+ P16+ Dok R Cancer Res2014
23 CANCER OF THE OROPHARYNX (NCCN 2014) National Comprehensive Cancer Network Clinical Guidelines in Oncology: Head and Neck cancer Version 2,2014
24 Survival rates by tumor HPV status Regimen Time HPV+ HPV- P-value I + C-XRT 2-year 95% 62% (E2399) C-XRT 3-year ~90% ~60% <0.001 XRT+/-S 5-year 81% 36% S+/-XRT 5-year 79% 46% Hammarstedt Mol Oncol; Licitra JCO; Fakhry JNCI; Gillison
25 Trotti et al Lancet Oncol 2007
26
27 WHAT S NEXT? Separate trials for HPV+ and HPV- disease Canwe de-intensifytreatment in low risk HPV+/ nonsmokers whilemaintingoverall survival What are the means to customize radiotherapy? dose Fractionation schedules Customize radiotherapy volumes Follow up Concomitant therapies
28 1.DOSE REDUCTION dose Fractionation schedules Customize radiotherapy Concomitant volumes therapies Follow up
29 1.DOSE REDUCTION dose Fractionation schedules Customize radiotherapy Concomitant volumes therapies Follow up HN002: randomizedphase2 trial forpatientswithp16+, non-smoking associated, locoregionally advanced OPC
30 DOSE REDUCTION dose Fractionation schedules Customize radiotherapy Concomitant volumes therapies Follow up ECOG 1308: randomized Phase 2 trial Cmelak A ASCO 2014, abstract LBA6006
31 DOSE REDUCTION dose Fractionation schedules Customize radiotherapy Concomitant volumes therapies Follow up ECOG 1308 Cmelak A ASCO 2014, abstract LBA6006 Marur JCO 2017
32 DOSE REDUCTION dose Fractionation schedules Customize radiotherapy Concomitant volumes therapies Follow up Quarterback
33 POSTOP DOSE REDUCTION dose Fractionation schedules Customize radiotherapy Concomitant volumes therapies Follow up
34 POSTOP DOSE REDUCTION dose Fractionation schedules Customize radiotherapy Concomitant volumes therapies Follow up PATHOS -Phase II trial 242 pts -P16+ OPSCC -T1T3N0N2b -transoral surgery to primary + neck dissection Low risk: no adjuvant therapy Intermediate risk: T3 tumours(or T1T2 tumourswith additional risk factors) N2a or N2b perineuraland/or vascular invasion or close margins (15mm) High risk positive(<1mm) margins and/or evidence of cervical lymph node extracapsular spread PORT 60Gy 6 wks PORT 50Gy 5 wks POCRT 60Gy 6 wks+ cisplat PORT 60Gy 6 wks
35 POSTOP DOSE REDUCTION dose Fractionation schedules Customize radiotherapy Concomitant volumes therapies Follow up ADEPT -P16+ OPSCC -Transoral resection T1- T4a primary negative margin -Neckdissection: ECE in nodal metastasis IMRT 60Gy/2Gy IMRT 60Gy/2Gy + cisplatinum40mg/m2 weekly
36 2.CONCOMITANT THERAPIES SUBSTITUTE CETUXIMAB FOR CISPLATIN? Fractionation dose schedules Customize radiotherapy volumes Follow up Concomitant therapies Bonner JA Lancet Oncol 2010
37 SUBSTITUTE CETUXIMAB FOR CISPLATIN? Fractionation dose schedules Customize radiotherapy volumes Follow up Concomitant therapies P16 is a strong prognosticfactor in locallyadvancedoropharyngealcancer: overall survival Rosenthal D ASCO 2014 Abstract 6001
38 SUBSTITUTE CETUXIMAB FOR CISPLATIN? Fractionation dose schedules Customize radiotherapy volumes Follow up Concomitant therapies Rosenthal D ASCO 2014 Abstract 6001
39 Concomitant therapies SUBSTITUTE CETUXIMAB FOR CISPLATIN? Biological rationale to use cetuximab in HPV+ disease? Controversial Inverse correlation EGFR gene copy number, EGFR protein expression and HPV status or p16 expression Immune stimulatory effect of C225 could potentiate the cytoxict-cell base antitumor immune response already present in HPV+ OPSCC EXTREME trial: cetuximabbeneficial independent of p16 status, SPECTRUM trial: panitumumab only effect in p16- disease Clinical rationale to use cetuximab in HPV+ disease? Controversial Tremplin study JCO 2013, Hitt ASCO 2013: toxicity difference cetuximab/cddp??
40 SUBSTITUTE CETUXIMAB FOR CISPLATIN? Fractionation dose schedules Customize radiotherapy volumes Follow up Concomitant therapies RTOG 1016: phase 3 trial in HPV-associated Oropharyngeal Cancer
41 Concomitant therapies SUBSTITUTE CETUXIMAB FOR CISPLATIN? RTOG 1016 TROG RT 70Gy 7 wks+ weekly cisplatin -P16+ OPSCC -st III (exclt1-2n1) or IV (exclt4, N3 anddistant M+) -ifsmoking history> 10 pack years: nodal disease must be N0- N2a RT 70Gy 7 wks+ weeklycetuximab De-ESCALaTE
42 3. REDUCE IRRADIATED VOLUMES dose volumes Fractionation schedules Customize radiotherapy Concomitant Follow up therapies Unilateral-only IMRT First Author, Year N N0-1, % T1-2, % Contralateral Neck failure, % Jackson, Kagei, O Sullivan, Rusthoven, Chronowski,
43 3. REDUCE IRRADIATED VOLUMES volumes PROTON therapy HPV+ HPV- Sioet al Int J RadiatOncolBiolPhys2016 Wang et al Head&Neck 2016
44 3. REDUCE IRRADIATED VOLUMES dose volumes Fractionation schedules Customize radiotherapy Concomitant Follow up therapies PROTON therapy WidesottL Int J RadiatOncolBiolPhys 2008
45 4. HYPOXIA MODIFICATION? Hypoxia modification Excellent radiotherapy response (Rishin JCO 2010; Ang NJEM 2010) No benefit from hypoxia targeted therapy (Lassen 2010 R&O; Rishin JCO 2010) Hypoxia seems not to affect prognosis (Toustrup, R&O 2012) Adapted from Toustrup K et al., R&O 2012
46 5. ALTERED FRACTIONATION? Fractionation schedules
47 6. IMMUNOTHERAPY? EconomopoulouP et al Ann Oncol 2016
48 ROLE OF FOLLOW UP AFTER RT 1, lymph node regression 2, metastasis dose volumes Fractionation schedules Customize radiotherapy Concomitant therapies Follow up both show distinct pattern in HPV+ versus HPV- disease
49 FOLLOW UP AFTER RT 1, lymph node regression During RT, enlargement of cystic lymph nodes has been described, with need for replanning dose volumes Fractionation schedules Customize radiotherapy Concomitant therapies Follow up Sanguineti G Head&Neck 2012
50 FOLLOW UP AFTER RT 1, lymph node regression After RT, lymph nodes involute more quickly, but undergo a prolonged process to eventual CR dose volumes Fractionation schedules Customize radiotherapy Concomitant therapies Follow up Huang H IJROBP 2013
51 FOLLOW UP AFTER RT 1, lymph node regression dose volumes Fractionation schedules Customize radiotherapy Concomitant therapies Follow up Huang H IJROBP 2013
52 FOLLOW UP AFTER RT 2, metastasis DM rateis similarforhpv+ andhpv-disease But DM tendtooccurlater Tend to be more disseminating, unusual sites Prolonged survival is described after salvage fordm dose volumes Fractionation schedules Customize radiotherapy Concomitant therapies Follow up HuangS OralOncol2013
53 FUTURE RT IN HPV+DISEASE Await results ongoing trials Other options in combination with RT: HPV vaccines As adjuvant therapy after CRT Example REALISTIC UK Concomitant with CRT and adjuvant Example EORTC studie TG4001 Immunotherapyanti PD-/PD-L1 toimproveanti-cancerimmune response New targeted drugs: PI3K, Aurora A, EGFR and Her2Neu
54 FUTURE? Targeting the altered DNA repair capacity
55 CONCLUSIONS +? - Altered fractionation Cetuximab Hypoxia modification Cisplatin Dose de-escalation Protontherapy DNA repair inhibitors Immunotherapy
56 CONCLUSIONS Oropharyngeal carcinoma is on the rise with HPV as important causative factor Many interesting trials are ongoing Results to be awaited, sufficient follow up Currentrecommendations: treatpatientsaccordingtotheirstage of diseaseat presentation, irrespective of HPV status Encourage enrollment in clinical trials
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
Locally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
Pre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer
Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Faye Johnson MD, PhD Associate Professor Thoracic/Head and Neck Medical Oncology August 2017 Objectives Review data that support concurrent chemo-
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
Head and Neck Cancer Update Sandro V Porceddu
Head and Neck Cancer Update Sandro V Porceddu Director, Radiation Oncology Research Princess Alexandra Hospital, Brisbane Associate Professor, University of Queensland President, Trans Tasman Radiation
Radio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology
Radio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology March 2018 > Half million new cases HNC/year in world 50-60% cured not cured
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21
State of the art for radiotherapy of SCCHN
State of the art for radiotherapy of SCCHN Less side effects Cured More organ & function preservation Head & neck cancer = 42 000 new cases / year in Europe Not cured Local failure Distant failure More
New Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy
TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy Anurag K. Singh, MD Professor of Medicine University at Buffalo School of Medicine Professor of Oncology Director of Radiation Research Roswell Park
Head and Neck cancer
Head and Neck cancer Medical Oncologist s Role in Multidisciplinary Teams - Focus on Adjuvant & Neo-adjuvant Therapy - Hye Ryun Kim, M.D. Yonsei Cancer Center, Medical Oncology Contents I. Introduction
Head and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
Self-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
SAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital
SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction
Comparing Alternative treatment Regimens for intermediate and high risk oropharyngeal cancer CompARE. Prof. Hisham Mehanna.
Comparing Alternative treatment Regimens for intermediate and high risk oropharyngeal cancer CompARE Prof. Hisham Mehanna Chief investigator: Hisham Mehanna Arm 1: Mehmet Sen Arm2: John Chester/Martin
Oral Cavity Cancer Combined modality therapy
Oral Cavity Cancer Combined modality therapy Dr. Christos CHRISTOPOULOS Radiation Oncologist Head and Neck Cancers Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Disclosure slide I have no
Head & Neck Cancer: When to Irradiate
Head & Neck Cancer: When to Irradiate ESO-ESMO Latin-America 2018 Talented students colleagues 1 > 15 different diseases for RT strategies NC NP OC OP H L 2 HPV Prognostic Marker >2010 Trial Cases Marker
Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
Protocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
Emerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,
Head and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) Amanda Psyrri, MD,FACP Attikon University Hospital Athens, Greece Learning objectives After reading and reviewing this material,
Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
Oral cavity cancer Post-operative treatment
Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection
(loco-regional disease)
(loco-regional disease) (oral cavity) (circumvillae papillae) (subsite) A (upper & lower lips) B (buccal membrane) C (mouth floor) D (upper & lower gingiva) E (hard palate) F (tongue -- anterior 2/3 rds
RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1.
RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. 550 000 NEW PATIENTS/YEAR WITH HEAD AND NECK CANCER ALL
Oral cancer: Prognosis & Treatment. Dr. Hani Al Sheikh Radhi
Oral cancer: Prognosis & Treatment Dr. Hani Al Sheikh Radhi Prognostic factors in Oral caner TNM staging T stage N stage M stage Site Histological Factors Vascular & Perineural Invasion Surgical Margins
Neoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
Current Clinical Trials for Oropharyngeal SCC in the HPV Era
Current Clinical Trials for Oropharyngeal SCC in the HPV Era Dr Caroline Connell Adelaide Radiotherapy Centre Page 1 3 May, 2016 Overview Advent of HPV associated Oropharyngeal SCC aetiology/risk factors
MANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS
MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS Kyle Arneson, MD PhD Avera Medical Group Radiation Oncology Avera Cancer Institute 16 th Annual Oncology Symposium September
Anatomy of Head of Neck Cancer
Anatomy of Head of Neck Cancer J. Robert Newman, MD The ENT Center of Central GA H&N Cancer Overview Most categories of cancer are represented in the H&N Squamous cell carcinoma most common mucosal cancer
Nasopharynx Cancer. 1 Feb Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar)
Nasopharynx Cancer 1 Feb 2016 Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar) Expert Panels Prof Mo Mo Tin Prof Michael Boyer Dr Raewyn Campbell Prof
State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck. Raul Giglio
State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck Raul Giglio Disclosures Nothing to disclose SCCHN Outline 1. General considerations: MTD 2. Epidemiology 3. Locoregional disease
Organ-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
Tumores de cabeza y cuello HPV+, una entidad diferente con tratamiento diferente?
Tumores de cabeza y cuello HPV+, una entidad diferente con tratamiento diferente? Coordinador Científico: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla, Santander Organizado por: Fundación
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
First of all, the pathophysiology
Welcome. My name is Eric Sturgis and I m a Professor in Head and Neck Surgery with a joint appointment in the Department of Epidemiology at The University of Texas MD Anderson Cancer Center. And today
HPV and Head and Neck Cancer: What it means for you and your patients
HPV and Head and Neck Cancer: What it means for you and your patients Financial Disclosure: None November 8, 2013 Steven J. Wang, MD Associate Professor Department of Otolaryngology-Head and Neck Surgery
Laryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
Locally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
Disclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
RADIATION THERAPY AND CHEMOTHERAPY IN LOCALLY ADVANCED CANCER OF THE HEAD AND NECK Carlos A. Perez, M.D. Former Chairman/Professor Emeritus
RADIATION THERAPY AND CHEMOTHERAPY IN LOCALLY ADVANCED CANCER OF THE HEAD AND NECK Carlos A. Perez, M.D. Former Chairman/Professor Emeritus Department of Radiation Oncology Mallinckrodt Institute of Radiology/
Humaan Papillomavirus en hoofd/halskanker. Pol Specenier
Humaan Papillomavirus en hoofd/halskanker Pol Specenier pol.specenier@uza.be Humaan Papillomavirus en hoofd/halskanker Hoofd/halskanker: incidentie en oorzaken Oropharynx carcinoom Incidentie HPV HPV en
AJCC Staging of Head & Neck Cancer (7 th edition, 2010) -LIP & ORAL CAVITY-
TX: primary tumor cannot be assessed T0: no evidence of primary tumor Tis: carcinoma in situ. T1: tumor is 2 cm or smaller AJCC Staging of Head & Neck Cancer (7 th edition, 2010) -LIP & ORAL CAVITY- T2:
Combining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
Accepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
A Case Review: Treatment-Naïve Patient with Head and Neck Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Recent Advances & Ongoing Challenges in Head & Neck Cancers
Recent Advances & Ongoing Challenges in Head & Neck Cancers Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard Medical School Boston, MA Disclosures
Piero Nicolai SURGERY FOR THE TREATMENT OF OROPHARYNGEAL CARCINOMA: STATE OF ART. Department of Otorhinolaryngology University of Brescia
Biology and technology contribution to clinical advancement: the case of oropharyngeal cancer Brescia May 8 th, 2009 SURGERY FOR THE TREATMENT OF OROPHARYNGEAL CARCINOMA: STATE OF ART Piero Nicolai Department
Case Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma
Case Scenario 1 History A 52 year old male with a 20 pack year smoking history presented with about a 6 month history of persistent hoarseness. The patient had a squamous cell carcinoma of the lip removed
FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma
Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.
3/12/2018. Head & Neck Cancer Review INTRODUCTION
Head & Neck Cancer Review Joseph Rosales, MD March 12, 2018 INTRODUCTION Epidemiology/Risk Factors Anatomy Presentation/Workup Treatment Surgery vs Radiation Chemotherapy Side effects Special circumstances
CANCERS of OROPHARYNX and HYPOPHARYNX. STAGING and TREATMENT
1 CANCERS of OROPHARYNX and HYPOPHARYNX STAGING and TREATMENT 2 1. Staging 2. General Principles of Treatment 3. Site Specific Treatment Guidelines 4. Selected Abstracts from Relevant Studies 3 1. Staging
Laryngeal and hypopharyngeal cancers
Laryngeal and hypopharyngeal cancers Induction Chemotherapy in combined modality approaches Atenas 16.09.2017 Ana Ferreira Castro, MD Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas
Q&A. Fabulous Prizes. Collecting Cancer Data: Pharynx 12/6/12. NAACCR Webinar Series Collecting Cancer Data Pharynx
Collecting Cancer Data Pharynx NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
Head and Neck Cancer. Mukund Seshadri DDS, PhD.!
Head and Neck Cancer Mukund Seshadri DDS, PhD Mukund.Seshadri@roswellpark.org 716-845- 1552 Overview Epidemiology Etiology and Risk factors Disease Biology Management Conventional Novel Targeted Therapies
PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
Treatment Deintensification Strategies for HPV-Related Head and Neck Cancer. Barbara Burtness, MD April, 2018
Treatment Deintensification Strategies for HPV-Related Head and Neck Cancer Barbara Burtness, MD April, 2018 Head and Neck Cancer Treatment Curative therapy with surgery or radiation Post operative adjuvant
Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit
Editorial Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit Hiroto Ishiki, Satoru Iwase Department of Palliative Medicine, The Institute of Medical
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide
CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
Human Papillomavirus and Head and Neck Cancer. Ed Stelow, MD
Human Papillomavirus and Head and Neck Cancer Ed Stelow, MD No conflict of interest Declaration Cancer 1974 Lancet Oncol 2016; 17: e477-8 JAMA 1984; 252: 1857 JAMA 1988;259(13):1943-1944 Clin Cancer Res
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed
The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
Present and Future of Head and Neck Cancer Therapy (Focus at systemic therapy)
Present and Future of Head and Neck Cancer Therapy (Focus at systemic therapy) Jan B; Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 1st Hellenic Conference
AJCC Cancer Staging 8 th edition. Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx
AJCC Cancer Staging 8 th edition Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx AJCC 7 th edition Lip and Oral cavity Pharynx Larynx KEY CHANGES Skin of head and neck (Vermilion of the lip)
Radiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
TOPICS. Primary Radiation Therapy. Targeted Therapy in Oncology. Principles of Radiation Therapy. Principles of Radiation Therapy
Peter B. Schiff, M.D., Ph.D. Department of Radiation Oncology Columbia University College of Physicians & Surgeons May 4, 2007 Targeted Therapy in Oncology Surgical Oncology Minimal invasive techniques
Diagnosis and what happens after referral
Diagnosis and what happens after referral Dr Kate Newbold Consultant in Clinical Oncology The Royal Marsden Women's cancers Breast cancer introduction 1 Treatment Modalities Early stage disease -larynx
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
Highlights in head and neck cancer
Special Edition Highlights in head and neck cancer P. Specenier, MD, PhD (Belg J Med Oncol 201;9:168-72) Management of locoregional lymph nodes The optimal management of the regional lymph nodes was studied
Rob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX
QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed
Benefits of Genomic Medicine: What to Tell the Patient
Benefits of Genomic Medicine: What to Tell the Patient Christine H. Chung, M.D. Associate Professor of Oncology Director, HNC Therapeutics Program Johns Hopkins University No Conflict of Interest to Disclose
3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations
Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations Troy G. Scroggins Jr. MD Chairman, Department of Radiation Oncology Ochsner Health Systems 1 Association of Postoperative Radiotherapy
ASCO Highlights Head and Neck Cancer
ASCO Highlights Head and Neck Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head &
Heterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
REIRRADIATION OF HEAD & NECK TARGETS
REIRRADIATION OF HEAD & NECK TARGETS WORKSHOP-Current challenges of patient re-irradiation 6-7 september 2018, Stockholm, Sweden Claes Mercke Karolinska Institute and Karolinska University Hospital STOCKHOLM
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.
Case Scenario 1 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of
Head and Neck Cancer Service
Dr Hoda Al Booz. MMedSci, MD, FFRRCSI, FRCR. Head and Neck Cancer Service Dr Hoda Al Booz Consultant in Clinical Oncology Bristol Cancer Institute Dr Hoda Al Booz. MMedSci, MD, FFRRCSI, FRCR. documents/
17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
Update on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12.
Update on Oral HPV Service and Related Research K Cuschieri, presented at Shine Meeting 25/09/12. Non Cervical Cancers with an HPV aetiology 1. Anal 2. Penile 3. Vulval 4. Vaginal 5. Component of head
Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.
Case Scenario 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of alcohol.
Survival Benefit of Chemotherapy in Oropharyngeal Cancer Patients Treated with. Surgery and Post-Operative Radiation. Fawaz Mohammed Makki
Survival Benefit of Chemotherapy in Oropharyngeal Cancer Patients Treated with Surgery and Post-Operative Radiation by Fawaz Mohammed Makki A thesis submitted in partial fulfillment of the requirements
Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
Cancer of the Head and Neck and. HPV Infection. Andrew Urquhart MD, FACS Dept. Otolaryngology/Head and Neck Surgery Marshfield Clinic
Cancer of the Head and Neck and HPV Infection Andrew Urquhart MD, FACS Dept. Otolaryngology/Head and Neck Surgery Marshfield Clinic Disclaimer I have no relevant financial relationships with the manufacturer(s)
The PreciseART Approach to Adaptive Radiotherapy with the RADIXACT System. Prof. Anne Laprie Radiation Oncologist
The PreciseART Approach to Adaptive Radiotherapy with the RADIXACT System Prof. Anne Laprie Radiation Oncologist Disclosure & Disclaimer An honorarium is provided by Accuray for this presentation The views